Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

New Upgrade:   Dedicated Screeners for Stocks & ETFs

Learn more
Market News Market Pulse Stocks News ETF News Crypto News

Surrozen, Inc.

Contributing Author

Recent Articles by Surrozen, Inc.

Oct-20
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million SRZN +5.45% GlobeNewswire
Oct-02
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema SRZN GlobeNewswire
Sep-08
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema SRZN -9.14% GlobeNewswire
Sep-02
Surrozen to Present at Upcoming Healthcare Investor Conferences SRZN GlobeNewswire
Aug-06
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update SRZN SRZN +18.39% GlobeNewswire
Jul-15
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
May-12
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
May-06
Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update SRZN SRZN -9.90% GlobeNewswire
Apr-28
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SRZN GlobeNewswire
Mar-23
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update SRZN GlobeNewswire
Feb-25
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
Feb-23
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SRZN GlobeNewswire
Feb-05
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN -10.15% SRZN +7.29% GlobeNewswire
Nov-25
Surrozen to Present at Upcoming Healthcare Investor Conferences SRZN +22.21% GlobeNewswire
Nov-12
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SRZN +6.80% SRZN -6.34% GlobeNewswire
Nov-07
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update SRZN GlobeNewswire
Nov-05
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
Sep-04
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SRZN GlobeNewswire
Sep-03
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
Aug-28
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN GlobeNewswire
Aug-08
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update SRZN +5.87% GlobeNewswire
Aug-06
Surrozen to Present at Upcoming Healthcare Investor Conference SRZN SRZN -12.83% GlobeNewswire
May-14
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway SRZN -9.72% GlobeNewswire
May-09
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update SRZN GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)